On September 1, the Food and Drug Administration issued draft guidance for post-warning letter meeting requests under the Generic Drug User Fee Amendments. Our FDA Compliance & Enforcement Team ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback